BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 33067394)

  • 1. Selective tumor antigen vaccine delivery to human CD169
    Affandi AJ; Grabowska J; Olesek K; Lopez Venegas M; Barbaria A; Rodríguez E; Mulder PPG; Pijffers HJ; Ambrosini M; Kalay H; O'Toole T; Zwart ES; Kazemier G; Nazmi K; Bikker FJ; Stöckl J; van den Eertwegh AJM; de Gruijl TD; Storm G; van Kooyk Y; den Haan JMM
    Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27528-27539. PubMed ID: 33067394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional CD169 on Macrophages Mediates Interaction with Dendritic Cells for CD8
    van Dinther D; Veninga H; Iborra S; Borg EGF; Hoogterp L; Olesek K; Beijer MR; Schetters STT; Kalay H; Garcia-Vallejo JJ; Franken KL; Cham LB; Lang KS; van Kooyk Y; Sancho D; Crocker PR; den Haan JMM
    Cell Rep; 2018 Feb; 22(6):1484-1495. PubMed ID: 29425504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Protein and Peptide Targeting for the Development of a CD169-Based Vaccination Strategy Against Melanoma.
    van Dinther D; Veninga H; Revet M; Hoogterp L; Olesek K; Grabowska J; Borg EGF; Kalay H; van Kooyk Y; den Haan JMM
    Front Immunol; 2018; 9():1997. PubMed ID: 30237798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposome induction of CD8
    Grabowska J; Affandi AJ; van Dinther D; Nijen Twilhaar MK; Olesek K; Hoogterp L; Ambrosini M; Heijnen DAM; Klaase L; Hidalgo A; Asano K; Crocker PR; Storm G; van Kooyk Y; den Haan JMM
    J Control Release; 2021 Mar; 331():309-320. PubMed ID: 33493613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted delivery of lipid antigen to macrophages via the CD169/sialoadhesin endocytic pathway induces robust invariant natural killer T cell activation.
    Kawasaki N; Vela JL; Nycholat CM; Rademacher C; Khurana A; van Rooijen N; Crocker PR; Kronenberg M; Paulson JC
    Proc Natl Acad Sci U S A; 2013 May; 110(19):7826-31. PubMed ID: 23610394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD169 Defines Activated CD14
    Affandi AJ; Olesek K; Grabowska J; Nijen Twilhaar MK; Rodríguez E; Saris A; Zwart ES; Nossent EJ; Kalay H; de Kok M; Kazemier G; Stöckl J; van den Eertwegh AJM; de Gruijl TD; Garcia-Vallejo JJ; Storm G; van Kooyk Y; den Haan JMM
    Front Immunol; 2021; 12():697840. PubMed ID: 34394090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD169
    Grabowska J; Lopez-Venegas MA; Affandi AJ; den Haan JMM
    Front Immunol; 2018; 9():2472. PubMed ID: 30416504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of Liposomes for Antigen Targeting to Splenic CD169
    Nijen Twilhaar MK; Czentner L; Grabowska J; Affandi AJ; Lau CYJ; Olesek K; Kalay H; van Nostrum CF; van Kooyk Y; Storm G; Haan JMMD
    Pharmaceutics; 2020 Nov; 12(12):. PubMed ID: 33255564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD169+ Subcapsular Macrophage Role in Antigen Adjuvant Activity.
    Lisk C; Yuen R; Kuniholm J; Antos D; Reiser ML; Wetzler LM
    Front Immunol; 2021; 12():624197. PubMed ID: 33815376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelets interact with CD169
    Grabowska J; Léopold V; Olesek K; Nijen Twilhaar MK; Affandi AJ; Brouwer MC; Jongerius I; Verschoor A; van Kooten C; van Kooyk Y; Storm G; van 't Veer C; den Haan JMM
    Front Immunol; 2023; 14():1290272. PubMed ID: 38054006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Delivery of Antigen to Activated CD169
    Edgar LJ; Kawasaki N; Nycholat CM; Paulson JC
    Cell Chem Biol; 2019 Jan; 26(1):131-136.e4. PubMed ID: 30393066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal Nanovaccine Containing α-Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8
    Grabowska J; Stolk DA; Nijen Twilhaar MK; Ambrosini M; Storm G; van der Vliet HJ; de Gruijl TD; van Kooyk Y; den Haan JMM
    Vaccines (Basel); 2021 Jan; 9(1):. PubMed ID: 33467048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In situ Delivery of Tumor Antigen- and Adjuvant-Loaded Liposomes Boosts Antigen-Specific T-Cell Responses by Human Dermal Dendritic Cells.
    Boks MA; Bruijns SCM; Ambrosini M; Kalay H; van Bloois L; Storm G; Gruijl T; van Kooyk Y
    J Invest Dermatol; 2015 Nov; 135(11):2697-2704. PubMed ID: 26083554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR.
    Klechevsky E; Flamar AL; Cao Y; Blanck JP; Liu M; O'Bar A; Agouna-Deciat O; Klucar P; Thompson-Snipes L; Zurawski S; Reiter Y; Palucka AK; Zurawski G; Banchereau J
    Blood; 2010 Sep; 116(10):1685-97. PubMed ID: 20530286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cationic liposomes loaded with a synthetic long peptide and poly(I:C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity.
    Varypataki EM; van der Maaden K; Bouwstra J; Ossendorp F; Jiskoot W
    AAPS J; 2015 Jan; 17(1):216-26. PubMed ID: 25387996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of CD8⁺ T Cell Responses after Melanoma Antigen Targeting to CD169⁺ Antigen Presenting Cells in Mice and Humans.
    van Dinther D; Lopez Venegas M; Veninga H; Olesek K; Hoogterp L; Revet M; Ambrosini M; Kalay H; Stöckl J; van Kooyk Y; den Haan JMM
    Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30764534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
    Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
    Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted delivery of herpes simplex virus glycoprotein D to CD169
    Shen W; Wang C; Jiang J; He Y; Liang Q; Hu K
    J Control Release; 2024 Jan; 365():208-218. PubMed ID: 37981051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens.
    Fehres CM; Kalay H; Bruijns SC; Musaafir SA; Ambrosini M; van Bloois L; van Vliet SJ; Storm G; Garcia-Vallejo JJ; van Kooyk Y
    J Control Release; 2015 Apr; 203():67-76. PubMed ID: 25656175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.